Last reviewed · How we verify
Azacitidine for Intravenous Infusion — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Azacitidine for Intravenous Infusion (Azacitidine for Intravenous Infusion) — Aptose Biosciences Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Azacitidine for Intravenous Infusion TARGET | Azacitidine for Intravenous Infusion | Aptose Biosciences Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Azacitidine for Intravenous Infusion CI watch — RSS
- Azacitidine for Intravenous Infusion CI watch — Atom
- Azacitidine for Intravenous Infusion CI watch — JSON
- Azacitidine for Intravenous Infusion alone — RSS
Cite this brief
Drug Landscape (2026). Azacitidine for Intravenous Infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/azacitidine-for-intravenous-infusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab